431 related articles for article (PubMed ID: 33865909)
1. Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
Nachit M; Kwanten WJ; Thissen JP; Op De Beeck B; Van Gaal L; Vonghia L; Verrijken A; Driessen A; Horsmans Y; Francque S; Leclercq IA
J Hepatol; 2021 Aug; 75(2):292-301. PubMed ID: 33865909
[TBL] [Abstract][Full Text] [Related]
2. A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients.
Nachit M; Lanthier N; Rodriguez J; Neyrinck AM; Cani PD; Bindels LB; Hiel S; Pachikian BD; Trefois P; Thissen JP; Delzenne NM
JHEP Rep; 2021 Aug; 3(4):100323. PubMed ID: 34355155
[TBL] [Abstract][Full Text] [Related]
3. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.
Nachit M; De Rudder M; Thissen JP; Schakman O; Bouzin C; Horsmans Y; Vande Velde G; Leclercq IA
J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):144-158. PubMed ID: 33244884
[TBL] [Abstract][Full Text] [Related]
4. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Li G; Rios RS; Wang XX; Yu Y; Zheng KI; Huang OY; Tang LJ; Ma HL; Jin Y; Targher G; Byrne CD; Pan XY; Zheng MH
Br J Nutr; 2022 Jun; 127(11):1613-1620. PubMed ID: 34176541
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.
Nachit M; Dioguardi Burgio M; Abyzov A; Garteiser P; Paradis V; Vilgrain V; Leclercq I; Van Beers BE
Eur Radiol; 2024 Mar; 34(3):1461-1470. PubMed ID: 37658893
[TBL] [Abstract][Full Text] [Related]
6. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
7. Muscle fat contents rather than muscle mass determines nonalcoholic steatohepatitis and liver fibrosis in patients with severe obesity.
Han E; Kim MK; Lee HW; Ryu S; Kim HS; Jang BK; Suh Y
Obesity (Silver Spring); 2022 Dec; 30(12):2440-2449. PubMed ID: 36319600
[TBL] [Abstract][Full Text] [Related]
8. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
9. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease.
Dasarathy J; Periyalwar P; Allampati S; Bhinder V; Hawkins C; Brandt P; Khiyami A; McCullough AJ; Dasarathy S
Liver Int; 2014 Jul; 34(6):e118-27. PubMed ID: 24118743
[TBL] [Abstract][Full Text] [Related]
10. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study.
Ooi GJ; Burton PR; Bayliss J; Raajendiran A; Earnest A; Laurie C; Kemp WW; McLean CA; Roberts SK; Watt MJ; Brown WA
Obes Surg; 2019 Jan; 29(1):99-108. PubMed ID: 30229460
[TBL] [Abstract][Full Text] [Related]
11. Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression.
Hsieh YC; Joo SK; Koo BK; Lin HC; Lee DH; Chang MS; Park JH; So YH; Kim W;
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):388-397.e10. PubMed ID: 35101634
[TBL] [Abstract][Full Text] [Related]
12. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
[TBL] [Abstract][Full Text] [Related]
13. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
14. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
[TBL] [Abstract][Full Text] [Related]
16. Association of Body Composition and Sarcopenia with NASH in Obese Patients.
Schmitz SM; Schooren L; Kroh A; Koch A; Stier C; Neumann UP; Ulmer TF; Alizai PH
J Clin Med; 2021 Aug; 10(15):. PubMed ID: 34362228
[TBL] [Abstract][Full Text] [Related]
17. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
[TBL] [Abstract][Full Text] [Related]
18. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
19. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]